Your Article Summary
See Latest ArticlesAdvances in the pathogenesis and treatment of IBD
Clinical Immunology, 06/18/09
Braus NA et al. - Medical therapy is with mesalamine compounds, corticosteroids, immunomodulators and/or biologics that target TNF alpha signaling or alpha 4-integrin-mediated trafficking. Investigational agents include those targeted against other cytokines and costimulatory molecules or designed to promote immune regulation such as exposure to helminths which is a focus of this review.
Related Articles
Novel Diagnostic and Prognostic Modalities in Inflammatory Bowel Disease
Gastroenterology Clinics of North America, 11/17/09
Relevance Score: 83%
Pregnancy and Inflammatory Bowel Disease
Gastroenterology Clinics of North America, 11/17/09
Relevance Score: 83%
Pathogenesis of inflammatory bowel disease (IBD)
The Internet Journal of Gastroenterology, 11/13/09
Relevance Score: 83%
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
The Lancet, 11/09/09
Relevance Score: 83%
Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history
Expert Review of Gastroenterology & Hepatology, 10/13/09
Relevance Score: 83%
Today in Gastrointestinal/Hepatic...keeping you current
Receive free subspecialty "5-minute updates" via email
Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels
Mucosal Immunology, 12/07/09
Small-for-size liver graft injury--impact on tumor behavior
Transplantation Reviews, 12/07/09
Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease
Clinical and Experimental Immunology, 12/04/09